Peer-Reviewed Paper Featuring Titan Medical’s Single-Port Robotic Surgical Platform in General Surgery Published in Surgica...
January 14 2019 - 8:00AM
Business Wire
Titan Medical Inc. (TSX: TMD) (Nasdaq: TMDI) (“Titan” or the
“Company”), a medical device company focused on the design and
development of a single-port robotic surgical system for
application in minimally invasive surgery (“MIS”), announces that a
peer-reviewed multi-faculty paper featuring Titan’s single-port
platform has been published in the January 2019 issue of Surgical
Endoscopy. The paper highlights the feasibility, safety and ease of
use of Titan’s single-port robotic technology for general surgery
procedures and is available here.
This European experience paper was authored by Barbara Seeliger,
M.D., Michele Diana, M.D., Jacques Marescaux, M.D., FACS, FRCS and
Lee Swanstrom, M.D., FACS, from IHU-Strasbourg Institute of
Image-Guided Surgery in France; Jelle Ruurda, M.D., Ph.D. from
University Medical Center in Utrecht, the Netherlands; and
Konstantinos Konstantinidis, M.D., Ph.D., FACS from Athens Medical
Center in Greece.
“We’re delighted this multi-faculty paper of extensive
preclinical work conducted under the guidance of internationally
renowned general surgeons has been published in a well-respected,
peer-reviewed surgical endoscopy journal,” said David McNally,
president and chief executive officer of Titan Medical. “It is
exciting and validating to see the feasibility, safety and ease of
use of our single-port technology demonstrated in the hands of
these KOL surgeons. The feedback from this experience was
instrumental in driving the system enhancements of our
next-generation platform, which we announced last week. We look
forward to providing this newest system to our surgeon champions in
the coming months as we progress toward U.S. and EU regulatory
filings later this year.”
Dr. Swanstrom said, “The feasibility studies conducted at IHU
Strasbourg with Titan’s single-port platform demonstrated that the
technology can be safely used in a wide variety of general surgery
procedures. Additionally, I believe the 3D HD visualization,
ergonomic interface and controls dramatically minimized the
learning curve for this new technology. The IHU-Strasbourg team is
pleased to be able to evaluate this enabling technology and we look
forward to using it to expand the frontiers of single-port
surgery.”
“I am happy to be part of this multi-faculty feasibility study
evaluating Titan’s enabling single-port robotic platform,”
commented Dr. Ruurda. “Single-port robotic surgery with the right
tools and capabilities like Titan’s supports the natural evolution
of minimally invasive surgery to fewer incisions. The study showed
that a variety of general surgery procedures were completed safely,
and my experience demonstrated the technology offers versatility in
multi-quadrant upper GI and lower GI procedures.”
Dr. Konstantinidis added, “It took me very little time to adjust
to Titan’s single-port platform during the evaluation of the
technology. The 3D HD visualization, natural handle interface,
dextrous end-effectors and highly ergonomic posture should greatly
facilitate the adoption of this platform. I am very excited about
the enhancements incorporated into the next-generation platform
based on the feedback from our study, as there is no doubt in my
mind that single-port robotic surgery is the next frontier.”
About Titan Medical Inc.
Titan Medical Inc. is focused on computer-assisted robotic
surgical technologies for application in minimally invasive
surgery. The Company is developing the SPORT Surgical System, a
single-port robotic surgical system comprised of a
surgeon-controlled patient cart that includes a 3D high-definition
vision system and multi-articulating instruments for performing MIS
procedures, and a surgeon workstation that provides an advanced
ergonomic interface to the patient cart and a 3D endoscopic view
inside the patient’s body. Titan intends to initially pursue
focused surgical indications for the SPORT Surgical System, which
may include one or more of gynecologic, urologic, colorectal or
general abdominal procedures.
For more information, please visit the Company’s website at
www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking statements” which
reflect the current expectations of management of the Company’s
future growth, results of operations, performance and business
prospects and opportunities. Wherever possible, words such as
“may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”,
“expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements. These statements reflect management’s current beliefs
with respect to future events and are based on information
currently available to management. Forward-looking statements
involve significant risks, uncertainties and assumptions. Many
factors could cause the Company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements, including, without limitation,
those listed in the “Risk Factors” section of the Company’s Annual
Information Form dated March 31, 2018 (which may be viewed at
www.sedar.com). Should one or more of these risks or uncertainties
materialize, or should assumptions underlying the forward-looking
statements prove incorrect, actual results, performance or
achievements may vary materially from those expressed or implied by
the forward-looking statements contained in this news release.
These factors should be considered carefully, and prospective
investors should not place undue reliance on the forward-looking
statements. Although the forward-looking statements contained in
the news release are based upon what management currently believes
to be reasonable assumptions, the Company cannot assure prospective
investors that actual results, performance or achievements will be
consistent with these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190114005467/en/
LHA Investor RelationsKim Sutton Golodetz(212)
838-3777kgolodetz@lhai.comorBruce Voss(310)
691-7100bvoss@lhai.com
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Apr 2024 to May 2024
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From May 2023 to May 2024